Pathology Presents: Dr. Lillian Siu

This event has ended.

Speaker

Lillian L. Siu, MD
Professor
BMO Chair in Precision Genomics
University of Toronto

Faculty Sponsor

Student: Nandita Kumar


Date & Time

October 28, 2020 at 1:30pm - 2:30pm

Location

https://washington.zoom.us/j/91707495151?pwd=UlZ5Z1FCZGJxUjJwNk5yalBDVk1xZz09

Calendar

Pathology Presents

Export
Add to Calendar 10/28/2020 01:30 PM 10/28/2020 02:30 PM America/Los_Angeles Pathology Presents: Dr. Lillian Siu Pathology Presents: Dr. Lillian Siu

Lillian L. Siu, MD
Professor
BMO Chair in Precision Genomics
University of Toronto
Lillian L. Siu, MD BMO Chair in Precision Genomics Professor of Medicine, Princess Margaret Cancer Centre, Toronto, Canada   "Translational Research to Identify Predictive Biomarkers for Immunotherapy" Immunotherapy especially checkpoint inhibitors such as antibodies directed against the programmed death protein and its ligand (anti-PD1 and anti-PD-L1 antibodies) have changed the treatment paradigm of many cancers, including head and neck cancer.  However, biomarkers to identify those who may benefit from checkpoint inhibitors have been limited to PD-L1 status by immunohistochemistry and tumor mutational burden by next generation sequencing. In this seminar, several non-invasive biomarkers, including liquid biopsy to quantify circulating tumor DNA (ctDNA) (Bratman et al. Nat Cancer 2020), microbiome assessments to determine the effects of oral and gut microbiota, and also radiomic evaluations of conventional radiological imaging, to determine if these multi-omic biomarkers may off additional insights on patient selection for immunotherapy.
https://washington.zoom.us/j/91707495151?pwd=UlZ5Z1FCZGJxUjJwNk5yalBDVk1xZz09 false MM/DD/YYYY

Description

Lillian L. Siu, MD

BMO Chair in Precision Genomics

Professor of Medicine, Princess Margaret Cancer Centre, Toronto, Canada

 

"Translational Research to Identify Predictive Biomarkers for Immunotherapy"

Immunotherapy especially checkpoint inhibitors such as antibodies directed against the programmed death protein and its ligand (anti-PD1 and anti-PD-L1 antibodies) have changed the treatment paradigm of many cancers, including head and neck cancer.  However, biomarkers to identify those who may benefit from checkpoint inhibitors have been limited to PD-L1 status by immunohistochemistry and tumor mutational burden by next generation sequencing. In this seminar, several non-invasive biomarkers, including liquid biopsy to quantify circulating tumor DNA (ctDNA) (Bratman et al. Nat Cancer 2020), microbiome assessments to determine the effects of oral and gut microbiota, and also radiomic evaluations of conventional radiological imaging, to determine if these multi-omic biomarkers may off additional insights on patient selection for immunotherapy.